Advertisement

Topics

Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility

2014-08-27 03:31:41 | BioPortfolio

Summary

The experimental focus of this project is on the interaction of DHEA treatment on pregnancy in women with otherwise unexplained infertility and evidence of premature ovarian aging (POA).

Description

Recruitment:

Eligible patients will be recruited by advertising on the web and in newspaper. We will screen women under 38 years old with regular menstrual cycles and more than one year of infertility.

Experimental plan:

1. Informed consent

2. Baseline studies

- Antral follicle counts on Day 2 - 3 of cycle

- Day 3 Serum FSH, LH, E2, Prog, DHEA, DHEAS, testosterone, AMH, Fragile X

3. Randomization for pretreatment

- Group A: DHEA (25 mg three times per day)

- Group B: Placebo

4. Monitoring during treatment

- All participants will have:

- USG for follicle measurement

- Repeat serum, FSH, E2, DHEA, DHEAS, testosterone, AMH monthly during treatment.

- Physical examination

- Completion of study questionnaire regarding possible androgen effects of treatment

5. Analysis plan:

- Primary Outcome

- Pregnancy

- Pregnancy rates will be compared using logistic regression with age and pre-treatment AMH as covariates.

- Secondary Outcomes

- Endocrine Factors

- Androgen side effects

- Primary analysis. We will perform a factorial ANOVA for the two pretreatment factors DHEA and Placebo. Baseline AMH and age as main covariates

- Secondary analysis.

- Examine rate of change of estradiol and other endocrine response over the four cycles of pretreatment

- Compare antral follicle counts across pretreatment cycles between groups

- Compare possible androgen related effects

- Power considerations:

- Power assumptions: alpha 0.05; 80% power

- Pregnancy rate for unexplained infertility is 2% per cycle.

- Intervention will improve pregnancy rate to 5% per cycle.

- Patients will be treated for 8 cycles.

- Cumulative pregnancy rate for control patients - 13%

- Cumulative pregnancy rate for Treated patients - 30%

- Require 91 patients to complete treatment in each group.

- Allow for 20% dropout ( 91* 1.2) will need 109 patients randomized to each group.

- Randomization:

Randomization will be by permuted blocks in order to maintain an even distribution among the groups (because of the small numbers of participants)

- Human subjects issues

- Potential risks associated with DHEA use

- Potential risk of delay of treatment for 8 months and possible natural continued loss of fertility

- Informed consent issues

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

Ovarian Aging

Intervention

Dehydroepiandrosterone

Location

Center for Human Reproduction
New York
New York
United States
10021

Status

Recruiting

Source

Center for Human Reproduction

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:31:41-0400

Clinical Trials [1313 Associated Clinical Trials listed on BioPortfolio]

Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)

The experimental focus of this project is on the interaction of DHEA treatment on pregnancy in women with open tubes, fertile male partners and evidence of premature ovarian failure.

Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment

The aim of this study was to evaluate the effect of dehydroepiandrosterone supplementation on in vitro fertilization performance and outcome among poor-responder patient.

Dehydroepiandrosterone Maintain Mitochondrial Quality of Cumulus Cells in Poor Ovarian Responders

To investigate whether the DHEA supplementation could improve mitochondrial quality in poor ovarian responders

Human Chorionic Gonadotropin (hCG) Priming Prior to Controlled Ovarian Hyperstimulation (COH) in Poor Responder In Vitro Fertilization (IVF) Patients

There is a decline in androgen concentration with ovarian aging. Also, ovarian response to COH in IVF cycles diminishes with ovarian aging. Recent evidence suggest that testosterone or D...

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency

OBJECTIVES: I. Determine the efficacy of dehydroepiandrosterone (DHEA), an androgen replacement hormone, for patients with primary adrenal insufficiency (Addison's disease).

PubMed Articles [3100 Associated PubMed Articles listed on BioPortfolio]

Effects of icariin on ovarian function in d-galactose-induced aging mice.

In this study, effects of icariin (Ica) on were examined in a mouse model of d-galactose (D-gal)-induced ovarian aging. Kunming white mice were divided into three groups: aging group induced with D-ga...

Effect of dehydroepiandrosterone on the liver of perimenopausal rat: multiple doses study.

Dehydroepiandrosterone (DHEA) is a widespread nutritional "anti-aging" supplement. Exogenous supplementation of DHEA is now being commonly used to augment ovarian stimulation in perimenopausal women w...

Identification and characterization of human ovary-derived circular RNAs and their potential roles in ovarian aging.

Circular RNAs (circRNAs) have recently been shown to exert effects on multiple pathological processes by acting as miRNA sponges. However, the roles of circRNAs in ovarian senescence are largely unkno...

Correction: Repeated superovulation increases the risk of osteoporosis and cardiovascular diseases by accelerating ovarian aging in mice.

Testosterone, androstenedione and dehydroepiandrosterone concentrations in pregnant Spanish Purebred mare.

Androgens modulate maternal ovarian activity, embryo implantation and correct placental development. The objective of this study was to establish reference values for testosterone (T), androstenedione...

Medical and Biotech [MESH] Definitions

A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.

The process of aging due to changes in the structure and elasticity of the skin over time. It may be a part of physiological aging or it may be due to the effects of ultraviolet radiation, usually through exposure to sunlight.

Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.

Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.

A complication of OVULATION INDUCTION in infertility treatment. It is graded by the severity of symptoms which include OVARY enlargement, multiple OVARIAN FOLLICLES; OVARIAN CYSTS; ASCITES; and generalized EDEMA. The full-blown syndrome may lead to RENAL FAILURE, respiratory distress, and even DEATH. Increased capillary permeability is caused by the vasoactive substances, such as VASCULAR ENDOTHELIAL GROWTH FACTORS, secreted by the overly-stimulated OVARIES.

More From BioPortfolio on "Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...


Searches Linking to this Trial